Imaging EGFR and HER2 by PET and SPECT: a review

Area of Science:

• Oncology
• Radiochemistry
• Molecular Imaging

Background:

• Targeted therapies for cancer often focus on Epidermal Growth Factor Receptor (EGFR) and Human Epidermal growth factor Receptor 2 (HER2) proteins.
• Predicting patient response to these therapies noninvasively is a significant clinical challenge.

Purpose of the Study:

• To review advances in developing noninvasive imaging agents for predicting cancer patient response to EGFR and HER2 targeted therapies.
• To provide an overview of PET and SPECT imaging agents targeting EGFR and HER2.

Main Methods:

• Literature review of research on PET and SPECT imaging agents for EGFR and HER2.
• Discussion of various imaging agent modalities, including small molecules and monoclonal antibodies.

Main Results:

• Significant progress has been made in developing selective PET and SPECT imaging agents for EGFR and HER2.
• Investigated agents range from small molecules to large biologics like monoclonal antibodies.

Conclusions:

• Noninvasive imaging agents show promise for predicting patient response to EGFR and HER2 targeted cancer therapies.
• Continued development of PET and SPECT agents is crucial for personalized oncology.